Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition. METHODS: We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent to an area under the concentration-time curve of 2) on days 1 and 8--with or without iniparib (at a dose of 5.6 mg per kilogram of body weight) on days 1, 4, 8, and 11--every 21 days. Primary end points were the rate of clinical benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for ≥6 months) and safety. Additional end points included the rate of objective response, progression-free survival, and overall survival. RESULTS: The addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34% to 56% (P=0.01) and the rate of overall response from 32% to 52% (P=0.02). The addition of iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months (hazard ratio for progression, 0.59; P=0.01) and the median overall survival from 7.7 months to 12.3 months (hazard ratio for death, 0.57; P=0.01). The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level. No significant difference was seen between the two groups in the rate of adverse events. CONCLUSIONS: The addition of iniparib to chemotherapy improved the clinical benefit and survival of patients with metastatic triple-negative breast cancer without significantly increased toxic effects. On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted. (Funded by BiPar Sciences [now owned by Sanofi-Aventis]; ClinicalTrials.gov number, NCT00540358.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The oncology literature has indicated that positive phase II data are not necessarily replicated in the phase III setting”
In the citing paper
“Furthermore, ongoing clinical trials for metastatic TNBC are including platinum agents in their treatment regimens (4, 36–38).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [36]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Cited by
Items 601–700 of 876
PARP inhibitors: pitfalls and promises
Infante, J. R., & Burris, H. A. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70276-6 · Cited by 5
Theilhaber, J., Chiron, M., Dreymann, J., Bergstrom, D. A., & Pollard, J. R. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03655-7 · Cited by 5
Gazzar, W. B. E., Albakri, K. A., Hasan, H., Badr, A. M., Farag, A. A., & Saleh, O. M. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231188903 · Cited by 5
Emerging therapies for triple-negative breast cancer
Anders, C. K., & Carey, L. (2012) · Breast Cancer Management · doi:10.2217/bmt.12.62 · Cited by 5
New treatment strategies in the management of breast cancer
Perez, E. A. (2011) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(11)70006-4 · Cited by 5
Ohno, S., Tanaka, K., Koga, C., Nishimura, S., Yamaguchi, H., Kawaguchi, H., Yoshiyama, T., & Nakamura, Y. (2011) · Breast Cancer · doi:10.1007/s12282-011-0277-2 · Cited by 5
DNA Damage and Repair in Cancer Therapy
Ibeas Millan Provencio, M. (2013) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.s8-002 · Cited by 5
Avery, T. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-60336-0_11 · Cited by 5
Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
Duma, N., Gast, K. C., Choong, G. M. Y., Leon-Ferre, R. A., & O'Sullivan, C. C. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0709-7 · Cited by 5
Biology and Treatment of Basal-Like Breast Cancer
Han, B., Audeh, W., Jin, Y., Bagaria, S. P., & Cui, X. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-634-4_5 · Cited by 5
Pharmacotherapeutic options for patients with refractory breast cancer
Fedele, P., Ciccarese, M., Surico, G., & Cinieri, S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1574751 · Cited by 5
Olaratumab for soft tissue sarcoma
Teyssonneau, D., & Italiano, A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1339031 · Cited by 5
Jhaveri, K. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.2712 · Cited by 5
Yardley, D. A., Brufsky, A., Coleman, R. E., Conte, P., Cortés, J., Glück, S., Nabholtz, J., O’Shaughnessy, J., Beck, R. M., Ko, A., et al. (2016) · Trials · doi:10.1186/s13063-016-1195-6 · Cited by 5
Self-citationOlaratumab failure in sarcomas: what are the lessons learned?
Italiano, A. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.030 · Cited by 5
Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer
Lynce, F., & Robson, M. (2023) · Cancer Treatment and Research · doi:10.1007/978-3-031-30065-3_6 · Cited by 4
Chemotherapy and HER2-Directed Therapy for Metastatic Breast Cancer
Waks, A. G., & Winer, E. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00069-6 · Cited by 4
Morse, W., Nawaz, H., & Choudhry, A. A. (2023) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-022-00159-8 · Cited by 4
Yu, H., & Wei, L. (2025) · Oncology Letters · doi:10.3892/ol.2025.14961 · Cited by 4
Targeting DNA repair: poly (ADP-ribose) polymerase inhibitors
Frey, M. K., & Pothuri, B. (2015) · Translational Cancer Research · doi:10.21037/3932 · Cited by 4
Distribución fenotípica del carcinoma de mama en Venezuela
Abreu, E. B., Betancourt, L., Godoy, A., Martínez, P., Romero, G., Bérgamo, L., & Cialoni, D. (2013) · Revista de Senología y Patología Mamaria · doi:10.1016/j.senol.2013.08.001 · Cited by 4
Beuzeboc, P. (2015) · EMC - Ginecología-Obstetricia · doi:10.1016/s1283-081x(15)70034-2 · Cited by 4
Poly(ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges
Khasraw, M., & Robson, M. E. (2011) · Clinical Investigation · doi:10.4155/cli.11.132 · Cited by 4
Breast Cancer and Benign Breast Disorders
Davidson, N. E. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00204-9 · Cited by 4
Sato, S., & Itamochi, H. (2015) · InTech eBooks · doi:10.5772/59513 · Cited by 4
PARP Inhibition to Enhance Response to Chemotherapy
Takebe, N., Quinn, M. F., Gupta, G., & Chen, A. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813753-6.00011-1 · Cited by 4
Epidemiology, Risk Factors, and Prevention
Bayraktar, S., & Arun, B. (2019) · Springer eBooks · doi:10.1007/978-3-030-04606-4_4 · Cited by 4
Inhibiteurs de la poly(ADP-ribose) polymerase et cancer du sein : bilan et perspectives
Gonçalvès, A. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2012.1553 · Cited by 4
Nouveautés sur les thérapies ciblées dans le cancer du sein
Coussy, F., Teixeira, L., Giacchetti, S., Cuvier, C., Hocini, H., & Espié, M. (2014) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2014.09.007 · Cited by 4
Systemic Treatment Considerations for Women with BRCA1/2-Associated Breast Cancer
Evron, E., Avraham, A., & Paluch–Shimon, S. (2014) · Current Breast Cancer Reports · doi:10.1007/s12609-014-0156-x · Cited by 4
Targeted Chemotherapeutics: An Overview of the Recent Progress in Effectual Cancer Treatment
Chaudhury, A., Kulhari, A., & Sheorayan, A. (2013) · Pharmacologia · doi:10.5567/pharmacologia.2013.535.552 · Cited by 4
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer
Mark, R. (2011) · doi:10.2217/ebo.11.100 · Cited by 4
Biard, D. S. F. (2011) · InTech eBooks · doi:10.5772/23681 · Cited by 4
Mechanisms in MedicinePreprint
Illari, P. K. (2016) · PhilSci-Archive (University of Pittsburgh) · doi:10.4324/9781315720739.ch5 · Cited by 4
Zeng, L., You, K., Lu, M., Hu, X., Zheng, C., Yao, L., Kang, B., Lin, S., Deng, X., Yan, J., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c04799 · Cited by 3
Targeted Therapy for Breast Cancer
Oh, H.-S. (2012) · Hanyang Medical Reviews · doi:10.7599/hmr.2012.32.2.112 · Cited by 3
Duan, Q., Feng, Y., Cao, L., Hu, L., Wang, J., Sun, F., Meng, Q., Zhou, M., Yu, J., & Gao, H. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251350630 · Cited by 3
Novel treatment options in the management of metastatic breast cancer.
Twelves, C., Vahdat, L. T., & Cortés, J. (2011) · PubMed · Cited by 3
Masitinib for gastrointestinal stromal tumors
Brahmi, M., & Cassier, P. A. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1180973 · Cited by 3
Stem Cells, Cell Differentiation, and Cancer
Dalerba, P. D., Clarke, M. F., Weissman, I. L., & Diehn, M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00007-2 · Cited by 3
Impact de l’imagerie sur le classement TNM : le M
de BAZELAIRE, C., Albiter, M., & de Kerviler, É. (2017) · Journal de radiologie diagnostique et interventionnelle · doi:10.1016/j.jradio.2017.01.009 · Cited by 3
Triple Negative Breast Cancer: A Review of Clinicopathologic Characteristics And Treatment Options
Porro, L. J., Mrazek, A. A., Washington, T. M., & Chao, C. (2014) · The Open Breast Cancer Journal · doi:10.2174/1876817201406010001 · Cited by 3
DNA Repair Pathways as a Potential Target for Radiosensitization
Toulany, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-45594-5_11 · Cited by 3
Assessing the Population Impact of Published Intervention Studies
Coffinier, C., Teutsch, S. M., & Fielding, J. E. (2015) · NAM Perspectives · doi:10.31478/201506e · Cited by 3
Parp Inhibitors: The Journey from Research Hypothesis to Clinical Approval
Naipal, K. A. T., & van Gent, D. C. (2015) · Personalized Medicine · doi:10.2217/pme.14.71 · Cited by 3
Retinoblastoma protein determines aggressiveness in triple-negative breast cancer
Jacob, J., Frampton, A. E., Castellano, L., Stebbing, J., & Krell, J. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.31 · Cited by 3
Advances in the Management of Triple Negative Breast Cancer
Hudis, C. A., & Traina, T. A. (2011) · doi:10.2217/9781780840123 · Cited by 3
[Molecular and genetic aspects of triple negative breast cancer and therapeutic implications].
Collignon, J., Struman, I., Tabruyn, S. P., Josse, C., Boukerroucha, M., Jérusalem, G., & Bours, V. (2011) · PubMed · Cited by 3
Epidemiology, Risk Factors, and Prevention
Bayraktar, S., & Arun, B. (2015) · Springer eBooks · doi:10.1007/978-3-319-22843-3_4 · Cited by 3
Ajabnoor, G. (2017) · MOJ Cell Science & Report · doi:10.15406/mojcsr.2017.04.00086 · Cited by 3
PARP1 inhibitors in breast cancer therapy. Mechanism of action and clinical use
Dolgasheva, D. S., Певзнер, А. М., Ibragimova, M. K., Litvyakov, N. V., & Tsyganov, M. M. (2020) · Tumors of female reproductive system · doi:10.17650/1994-4098-2020-16-1-55-64 · Cited by 3
Next-Generation Sequencing for Cancer Biomarker Discovery
Desai, A. N., & Jere, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-15811-2_7 · Cited by 3
Difference in Therapeutic Response Between Basal and Nonbasal Triple-Negative Breast Cancers
Bertucci, F., Finetti, P., Viens, P., & Birnbaum, D. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0121 · Cited by 3
Dent, R. A., & Bristow, R. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1990 · Cited by 3
PARP1 expression in breast cancer and effects of its inhibition in preclinical models
Parra, G. L., & Jetzabel (2012) · Repositori digital de la UPF (Universitat Pompeu Fabra) · Cited by 3
Han, M. İ., Atalay, P., & Basaran, G. S. (2026) · Gene · doi:10.1016/j.gene.2026.150201 · Cited by 2
Clinical Trials Investigating PARP Inhibitors as Single Agents
Irshad, S., & Tutt, A. N. J. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-14151-0_21 · Cited by 2
Ali, F., Iqbal, A., Azhar, I., Qayyum, A., Hassan, S. A., Hasan, M. S. A., Jawi, M., Hassan, H. M., Al‐Emam, A., & Sajid, M. (2024) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2024.108247 · Cited by 2
Synthetic Lethality with Homologous Recombination Repair Defects
Bryant, H. E., & Shall, S. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-14151-0_13 · Cited by 2
Present and Emerging Targeted Therapy for Metastatic Breast Cancer
Lorusso, V., Marech, I., Giampaglia, M., Tinelli, A., & Chiurì, V. E. (2012) · Journal of cancer research updates · doi:10.6000/1929-2279.2012.01.01.14 · Cited by 2
Administration sequence for multi-agent oncolytic regimens
Morales, A. S. R., Joy, J. K., & Zbona, D. M. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219895070 · Cited by 2
Hayat, M. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803508-5.00001-9 · Cited by 2
Nanomedicine-Based Combinational Therapy for Breast Cancer
Jain, P., Hassan, N., Farooq, U., Mohapatra, S., Alex, T. S., Fatima, M., Mirza, M. A., & Iqbal, Z. (2022) · Springer eBooks · doi:10.1007/978-981-19-5558-7_9 · Cited by 2
Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer
Chatterjee, P., Karn, R., Isaac, A. E., & Ray, S. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03191-9 · Cited by 2
PARP-1 inhibitors and radiotherapy sensitivity: future prospects for therapy?
Speers, C. W., Feng, F. Y.-C., & Pierce, L. J. (2014) · Breast Cancer Management · doi:10.2217/bmt.14.6 · Cited by 2
Innovation in myeloma treatments PARP excellence!
Fonseca, R. (2011) · Blood · doi:10.1182/blood-2011-10-381129 · Cited by 2
The Future of Chemotherapy in the Era of Personalized Medicine
Dieci, M. V., Guarneri, V., & Conte, P. (2012) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0094-4 · Cited by 2
Understanding Triple Negative Breast Cancer
Balani, S., & Katiyar, S. (2015) · Cited by 2
Treating Triple-Negative Breast Cancer: Where Are We?
Morikawa, A., & Seidman, A. D. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0032 · Cited by 2
Potential Therapeutic Targets in Triple Negative Breast Cancer
Azim, H. A., & Azim, H. A. (2015) · Current Breast Cancer Reports · doi:10.1007/s12609-015-0192-1 · Cited by 2
Cancer Stem Cells: Biology and Potential Therapeutic Applications
Mangoni, M., Sottili, M., Loi, M., Gerini, C., Meattini, I., & Livi, L. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_8 · Cited by 2
Planchard, D., & Leprieur, E. G. (2011) · Revue de Pneumologie Clinique · doi:10.1016/s0761-8417(11)70009-8 · Cited by 2
Targeting Cancer Stem Cells and the Tumor Microenvironment
Turdo, A., Todaro, M., & Stassi, G. (2015) · Springer eBooks · doi:10.1007/978-3-319-21030-8_16 · Cited by 2
Von der Diagnostik zur Therapie: Das dreifach negative Mammakarzinom
Naehrig, D. N., Dellas, S., Obermann, E. C., Weber, W. P., & Rochlitz, C. F. (2013) · Info Onkologie · doi:10.1007/s15004-013-0493-3 · Cited by 2
Can Early Clinical Trials Help Deliver More Precise Cancer Care?
Lim, J. S. J., Brown, J. S., & Bono, J. S. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812512-0.00009-9 · Cited by 2
In Vivo Phototheranostics Application of AIEgen‐based Probes
Gao, Z., Gao, H., & Ding, D. (2022) · Wiley eBooks · doi:10.1002/9781119643098.ch56 · Cited by 2
Molecular Progression of Breast Cancer and Personalized Medicine in Terms of Clinical Trials
Liaqat, S., Hussain, M., Aftab, K., Khalid, M., & Malik, S. S. (2022) · Springer eBooks · doi:10.1007/978-981-19-0197-3_15 · Cited by 2
Ibba, S. V., Luu, H., & Boulares, A. H. (2022) · PubMed · Cited by 2
Brief Overview of Breast Cancer Treatment
You, J. Y., Park, S., & Lee, E. S. (2023) · Springer eBooks · doi:10.1007/978-981-19-9044-1_4 · Cited by 2
Brandão, R. D. (2012) · Research Publications (Maastricht University) · doi:10.26481/dis.20121031rb · Cited by 2
Brca2deficiency andTrp53deregulation in pancreatic cancer: Implications for therapeutic targeting
Yee, N. S. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.11.16573 · Cited by 2
Reining in the Excessive Use of Medical Tests: What Are the Next Steps?
Smith, K. L., & Smith, T. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.0975 · Cited by 2
Xiao, G., Yan, J., Cai, Z., Wu, M., Zhang, R., Yang, X., Yao, Y., Xiong, Z., Ye, M., Zhang, J., et al. (2025) · medRxiv · doi:10.1101/2025.03.11.25323491 · Cited by 2
PARP inhibitors and their evolving role in breast cancer.
Roop, R. P., Ma, C. X., & Ellis, M. J. (2011) · PubMed · Cited by 1
Chromatin Marks H3K4me3 and H3K9me3 in Triple‐Negative Breast Cancer Cell Lines
Anjum, F., Kaushik, K., Salam, A., & Nandi, C. K. (2025) · Advanced Biology · doi:10.1002/adbi.202400752 · Cited by 1
Topuz, Ö. V., Arslan, E., & Usul, G. (2025) · Bagcilar Medical Bulletin · doi:10.4274/bmb.galenos.2025.69885 · Cited by 1
Stringer-Reasor, E. M., Saha, P., Kocherginsky, M., Lastra, R. R., Baker, G. M., Lenygel, E., Karrison, T. G., Olalde, L., Mokrzycki, E., Hahn, O. M., et al. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07783-7 · Cited by 1
Ma, X., Jia, S., Gao, T., Liu, J., Xin, T., Liu, Z., Yang, Y., Xiang, R., Gao, M., & Zhao, M. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70216 · Cited by 1
Emerging treatments for metastatic breast cancer: update from 2012
Thanopoulou, E., Schiavon, G., Allen, M. J., & Johnston, S. R. D. (2012) · Breast Cancer Management · doi:10.2217/bmt.12.57 · Cited by 1
Perspectives des thérapies ciblées dans le cancer du sein métastatique
Belmondo, L., Montana, M., Curti, C., Crozet, M. D., Rathelot, P., Penot-Ragon, C., & Vanelle, P. (2012) · Therapies · doi:10.2515/therapie/2012068 · Cited by 1
Emerging Prognostic and Predictive Biomarkers for Triple Negative Breast Cancer
Nag, S. M., Mane, A. D., & Gupta, S. (2014) · Current Breast Cancer Reports · doi:10.1007/s12609-014-0165-9 · Cited by 1
The role of platinum therapy in triple-negative breast cancer
Afghahi, A., & Telli, M. L. (2014) · Breast Cancer Management · doi:10.2217/bmt.14.21 · Cited by 1
Jang, P., Holleran, T., Burns, M. B., Governale, A., Lyu, Y. L., & Cai, L. (2014) · Cited by 1
The Role of BRCA1 and BRCA2 in Anticancer Drug Therapy
Shuen, A. Y., Reis-Filho, J. S., & Foulkes, W. D. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4741-2_6 · Cited by 1
Triple negative breast cancer: current status of the problem and unusual case of treatment
Муфазалов, Ф. Ф., & Sharipova, N. S. (2015) · Malignant tumours · doi:10.18027/2224-5057-2014-1-19-31 · Cited by 1
Patterns in target-directed breast cancer research
Torres, S., Simmons, C. E., Boileau, J.-F., McLeod, D., Martins, I., & Trudeau, M. (2016) · SpringerPlus · doi:10.1186/s40064-016-1736-1 · Cited by 1
Blood DNA methylation biomarkers for breast cancer risk
Brennan, K. (2013) · Spiral (Imperial College London) · doi:10.25560/23641 · Cited by 1
Ladislau, T., Klesia, P., Renata, D. S., Guimarães, I. D. S., Ftouni, S., Paulo, C. M., Iuri, C., Leticia, B. A., & Alice, L. (2013) · InTech eBooks · doi:10.5772/55284 · Cited by 1
Biologicals beim Ovarialkarzinom: Stand der Entwicklung
de Gregorio, N., Ebner, F. K., Janni, W., & Wöckel, A. (2013) · Der Gynäkologe · doi:10.1007/s00129-013-3212-0 · Cited by 1
The Role of Platinum Compounds for the Treatment of Breast Cancer
Graña, B., Fernández, N., & Balmañà, J. (2013) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0100-x · Cited by 1
Metadata
- Authors
- O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C.
- Affiliations
- Texas Oncology (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-20
- Volume
- 364
- Issue
- 3
- Pages
- 205-214
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2111429259
- Cited by
- 817
- References
- 32
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 6 · 2023: 22 · 2022: 23 · 2021: 30 · 2020: 27 · 2019: 30 · 2018: 47 · 2017: 52 · 2016: 42 · 2015: 72 · 2014: 90 · 2013: 94 · 2012: 133
- FWCI
- 70.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- metastatic triple-negative breast cancer, PARP inhibition, gemcitabine, carboplatin, combination chemotherapy, DNA repair deficiency, clinical benefit, progression-free survival, overall survival, adverse events, neutropenia, thrombocytopenia, drug safety and efficacy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Gemcitabine, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Deoxycytidine, Female, Humans, Neoplasm Metastasis, Survival Analysis, Carboplatin, Cross-Over Studies, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.